Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B: The Road Ahead

This article was originally published in The Tan Sheet

Executive Summary

With at least 44,000 Plan B comments still under review at FDA, it is unclear when the agency will take its next step toward a decision on the proposed switch. In the meantime, those seeking OTC sale of EC are not keeping quiet on the issue. With lawsuits pending and pharmacy access to the drug increasing among individual states, there is plenty in store for Plan B in the coming year..

You may also be interested in...

FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision

Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").

Plan B Pharmacy Access Sales Growth Offers Silver Lining To FDA Delay – Barr

Barr is testing a drugstore point-of-purchase program that directs consumers to ask their pharmacists about Plan B in states with pharmacy access to the emergency contraceptive

FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation

FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts